{"filings":[{"id":722156,"accession_number":"0001503802-26-000027","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-05-28T20:15:13+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Karyopharm shareholders approve equity plan amendments; board approves milestone-based PSU awards for executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 3M share increase under 2022 Equity Incentive Plan and 1.4M under ESPP at May 21 annual meeting.","Directors Barry E. Greene and Christy J. Oliger elected as Class I directors for three-year terms.","Board approved retention program granting PSUs vesting on clinical milestones; CEO Richard Paulson awarded 343,000 PSUs per award.","Named executives (CMO, CFO, CDO) each received 130,000-150,000 PSUs per award; total 3,838,380 PSUs granted to all eligible employees.","Board adopted further amendment to increase authorized shares by 950,000, subject to stockholder approval by May 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77682,"accession_number":"0001193125-26-222808","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-05-14T11:32:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.","Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.","Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.","Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.","Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104711,"accession_number":"0001503802-26-000011","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Karyopharm raises ~$50M via private placement and ATM; cash runway into late Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement with RA Capital Management closed March 26: 1.03M shares at $6.785, pre-funded warrants for 3.39M shares, and warrants for 4.42M shares at $10.00 exercise.","Gross proceeds from private placement ~$30M; net proceeds from ATM sales of 2.99M shares ~$19.8M.","Post-transaction shares outstanding 22.54M plus pre-funded warrants for 4.01M shares.","Management expects existing liquidity, net product revenue, and license revenue to fund operations into late Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104710,"accession_number":"0001193125-26-120770","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Karyopharm SENTRY trial meets spleen endpoint, misses symptom; DLBCL withdrawal agreed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SENTRY trial: 50% SVR35 at wk24 vs 28% for ruxolitinib alone (p<0.0001); Abs-TSS comparable, not significant.","Promising OS signal: HR 0.43 (95% CI 0.19–1.00, nominal p=0.0222); continued follow-up planned.","FDA requested withdrawal of accelerated approval for XPOVIO in DLBCL; company agreed, ceases development.","Private placement with RA Capital: ~$30M gross (1.03M shares at $6.785, pre-funded warrants); warrants at $10.","ATM sales in March 2026 raised ~$9.6M net; capital raise trigger satisfied for credit agreement amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104709,"accession_number":"0001503802-26-000006","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Karyopharm defers debt payments, requires $25M equity raise to extend runway past mid-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment to Credit Agreement defers June 2026 principal payment to September 10, 2026; interest due June 30 paid in kind.","Minimum liquidity covenant reduced to $10M through Oct 10, 2026 (from $25M) conditional on $25M+ equity raise before June 10, 2026.","Forbearance agreements with lenders and noteholders defer payment-related defaults through Sep 30, 2026, and liquidity covenant breaches through Oct 10, 2026.","Phase 3 XPORT-EC 042 top-line data still expected mid-2026; the amendments aim to extend cash runway beyond that readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104708,"accession_number":"0001193125-26-059349","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Karyopharm shareholders approve increase in authorized shares to 111M at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock raised from 53,333,333 to 106,000,000; total capital shares from 58,333,333 to 111,000,000.","Vote: 9,436,123 for, 3,213,329 against, 25,465 abstain; adjournment proposal also approved but not needed.","Certificate of amendment filed with Delaware Secretary of State on February 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104707,"accession_number":"0001193125-26-047670","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm FY2025 total rev $146M; XPOVIO $115M; net loss $196M; FY2026 guidance $130-150M; key trial readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).","FY2025 net loss $196.0M ($17.93/share) vs $76.4M prior year, driven by $62.4M loss on debt extinguishment.","Cash, cash equivalents and investments $64.1M at Dec 31, 2025 vs $109.1M at Dec 31, 2024; runway into Q2 2026.","FY2026 guidance: total revenue $130-150M, XPOVIO net product $115-130M, R&D+SG&A $230-245M.","Phase 3 SENTRY myelofibrosis trial top-line data expected March 2026; Phase 3 endometrial cancer data mid-2026."],"consensus_eps_estimate":-2.0342,"consensus_eps_actual":-17.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":146067000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104706,"accession_number":"0001193125-26-009738","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Karyopharm reports prelim FY2025 total revenue ~$145M; cash ~$64M; Phase 3 myelofibrosis data due March 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.","Cash and investments as of Dec 31, 2025 ~$64M; liquidity expected to fund operations into Q2 2026.","Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026; XPORT-EC-042 endometrial cancer data due mid-2026.","Completed strategic financing transactions to extend cash runway beyond SENTRY readout.","Global patient access expanded: selinexor approved in >50 countries; reimbursement in Spain and China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121001,"accession_number":"0001193125-25-261663","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).","Net loss $33.1M ($3.82/sh) vs $32.1M ($3.85/sh); operating loss improved 42% to $15.2M.","Phase 3 SENTRY myelofibrosis trial enrollment complete (353 pts); top-line data due March 2026.","Reaffirms FY2025 total rev guidance $140M-$155M, XPOVIO rev $110M-$120M; lowers expense guide to $235M-$245M.","Cash $46.2M at Sep 30 (proforma ~$78M after Oct 8 financing); expects liquidity into Q2 2026."],"consensus_eps_estimate":-3.1931,"consensus_eps_actual":-10.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":111988000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121000,"accession_number":"0001193125-25-239015","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Karyopharm closes $131M debt financing; issues 9% convertible notes, waives defaults","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $12.5M under amended credit agreement; issued $15M 2028 and $103.5M 2029 convertible notes at 9%.","Specified defaults under existing credit agreement waived via Oct 7, 2025 First Amendment.","As of Oct 14, 2025, common shares outstanding: 15,926,939.","Financing includes warrants and pre-funded warrants; previously announced on Oct 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120999,"accession_number":"0001193125-25-233983","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"KPTI closes $67.5M debt package, note exchanges & $8.75M equity; runway into Q2 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$27.5M new term loan (SOFR+10.25%), $25M interest/royalty deferrals, $15M liquidity covenant relief.","Exchanged $15M 2029 notes for new 9% 2028 notes and $24.25M Oct 2025 notes for stock & warrants.","Raised $8.75M via private placement of 7.2M shares and warrants at $6.64 exercise price.","Pro forma cash ~$36M; shares outstanding ~15.9M; total debt $112.5M term loan, $15M+$103.5M convert notes.","Lenders get board observer; interest payments paid-in-kind through March 2026, cash starts June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137611,"accession_number":"0001503802-25-000006","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Karyopharm Therapeutics director Mansoor Raza Mirza resigns from board effective Sept 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mansoor Raza Mirza, M.D. resigned from the Board of Directors due to competing professional demands.","Resignation effective September 8, 2025; not due to any disagreement with the Company.","Consulting agreement with Mirza Consulting terminated effective September 8, 2025.","Dr. Mirza also resigning as Chief Oncologist at Copenhagen University National Medical Center effective Oct 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137610,"accession_number":"0000950170-25-106236","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).","FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.","Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.","Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.","Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value."],"consensus_eps_estimate":-4.1805,"consensus_eps_actual":-7.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":67944000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137609,"accession_number":"0000950170-25-095167","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Karyopharm cuts workforce 20%, explores strategic alternatives including sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.","Board evaluating financing, merger/sale, restructuring, or debt refinancing; no deal yet.","Engaged with potential investors under confidentiality; discussions did not result in a transaction.","Committed to Phase 3 trials in myelofibrosis and endometrial cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154977,"accession_number":"0000950170-25-079009","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Karyopharm shareholders approve 450,000 share increase to equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Garen G. Bohlin and Zhen Su as Class III directors with 3,066,819 and 3,191,845 votes for, respectively.","Approved amendment to 2022 equity plan adding 450,000 shares; 2,606,928 for, 1,103,365 against, 344,880 abstain.","Advisory vote on named executive officer compensation passed: 2,716,951 for, 1,041,611 against, 296,611 abstain.","Advisory vote on say-on-pay frequency favored every year (3,263,514 votes); Board adopted annual frequency.","Ratified Ernst & Young as independent auditor for FY2025: 6,237,926 for, 210,714 against, 115,566 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154976,"accession_number":"0000950170-25-069176","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Reports Q1 2025 Revenue of $30.0M, Net Loss of $23.5M; Phase 3 SENTRY Trial Passes Futility Analysis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.","Phase 3 SENTRY trial (selinexor + ruxolitinib) passed futility analysis, is ~80% enrolled; target enrollment expected June/July 2025.","Phase 2 XPORT-MF-035 data: selinexor monotherapy achieved SVR25 in 67% of evaluable patients vs 38% with physician's choice.","Reaffirms full-year 2025 guidance: total revenue $140M–$155M, U.S. XPOVIO net product revenue $115M–$130M.","Cash, cash equivalents and investments $70.3M as of March 31, 2025; exploring alternatives to extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":30015000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173492,"accession_number":"0000950170-25-025640","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Karyopharm files 1-for-15 reverse stock split effective Feb 25 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split 1-for-15 effective Feb 25, 2025 at 5pm ET; post-split trading starts Feb 26.","Authorized shares reduced to 53,333,333; no fractional shares, cash paid in lieu.","Equity awards, warrants, and convertible notes adjusted proportionally.","New CUSIP number for common stock after split is 48576U205.","Purpose: regain compliance with Nasdaq minimum $1.00 bid price continued listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173491,"accession_number":"0000950170-25-022764","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).","FY2024 net loss $76.4M ($0.63 basic EPS) vs $143.1M ($1.25) prior year; cash $109.1M (Dec 2024) vs $192.4M.","Phase 3 SENTRY myelofibrosis trial: endpoint updated to Abs-TSS; top-line data expected 2H 2025; enrollment complete 1H 2025.","Phase 3 XPORT-EC-042 endometrial cancer trial modified: focus on pMMR/dMMR ineligible for checkpoint inhibitors; sample size 276; data mid-2026.","FY2025 guidance: total revenue $140-155M; US XPOVIO net product rev $115-130M; R&D+SG&A $240-255M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":145237000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173490,"accession_number":"0001193125-25-018385","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Karyopharm grants retention equity awards: 412,500 stock options and 206,250 RSUs to three executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Named executives Sohanya Chang, Stuart Poulton, and Reshma Rangwala each receive 137,500 options and 68,750 RSUs, effective Feb 28, 2025.","Options vest 25% on first anniversary, then monthly over 4 years; RSUs vest 50% on each of two consecutive anniversaries.","Full acceleration of awards if termination without cause or for good reason occurs within one year after a change-in-control event.","Exercise price of options equals the closing stock price on the Nasdaq on the grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173489,"accession_number":"0001193125-25-017223","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Karyopharm shareholders approve reverse stock split and share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved increase in authorized capital stock to 805M shares (common to 800M).","Approved reverse stock split at ratio 1:5 to 1:15; board to decide timing and exact ratio by Feb 28, 2025.","Reverse split: 74.8M votes for, 20.0M against; share increase: 71.6M for, 23.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173488,"accession_number":"0000950170-25-004591","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.","Phase 3 SENTRY trial (selinexor+ruxolitinib in MF) enrollment completion in 1H 2025, top-line data in 2H 2025.","Appointed Lori Macomber as CFO (Jan 3, 2025) and Brendan Strong as SVP IR (Dec 9, 2024).","Cash, equivalents, and investments ~$109M as of Dec 31, 2024; expected runway into Q1 2026 (excl. note repayment)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":145237000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173487,"accession_number":"0000950170-25-000092","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.","Annual base salary of $475,000; target annual bonus of 45% of base salary.","Inducement equity: option for 650,000 shares and 160,000 RSUs, vesting over 4 and 3 years.","Kristin Abate, interim principal financial officer, will step down on Jan 3, 2025.","Severance includes one month base salary per month of service (max 12 months), enhanced upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190477,"accession_number":"0001193125-24-269398","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Karyopharm pauses endometrial cancer program update; in talks with FDA about Phase 3 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company in discussions with FDA regarding evolving treatment landscape for endometrial cancer and its impact on Phase 3 XPORT-EC-042 trial.","Karyopharm will not discuss endometrial cancer program at Piper Sandler conference on Dec 3, 2024.","Company intends to provide update on endometrial cancer program after FDA discussion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190476,"accession_number":"0001193125-24-262541","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Karyopharm appoints Kristin Abate as VP, Chief Accounting Officer, effective Nov 20, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristin Abate appointed Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.","She continues as interim principal financial officer; designated as principal accounting officer.","Abate has been with Karyopharm since July 2019, most recently as VP Accounting, Corporate Controller, Assistant Treasurer.","Prior to Karyopharm, she spent 12 years at PricewaterhouseCoopers LLP; CPA with MS in Accountancy from Boston College."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190475,"accession_number":"0000950170-24-124067","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Karyopharm reduces office space by 46,278 sq ft, extends lease for remaining space through 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces leased premises by 46,278 rentable square feet (from 98,502 to 52,224) effective Sept 30, 2025.","Term for remaining 52,224 sq ft extended five years through Sept 30, 2030, with annual rent escalation.","Annual base rent for remaining space starts at $35.75/sq ft ($1.87M) and rises to $39.75/sq ft ($2.08M) by year 5.","Landlord provides $2,219,520 tenant improvement allowance ($42.50/sq ft) for work in the retained premises.","Tenant surrenders vacated portion on Sept 30, 2025, without required removal of certain initial alterations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190474,"accession_number":"0001193125-24-250984","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.","Net loss $32.1M ($0.26/share) vs $34.5M ($0.30/share) in Q3 2023; R&D expenses increased to $36.1M.","FY2024 total revenue guidance narrowed to $145-155M; XPOVIO revenue guidance narrowed to $110-115M.","Phase 3 SENTRY myelofibrosis trial endpoint changed to Abs-TSS; sample size increased to ~350; top-line data expected 2H 2025.","Cash and investments $133.9M; cash runway into Q1 2026 (excluding $24.5M convertible note due Oct 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":114695000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190473,"accession_number":"0001193125-24-248162","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Karyopharm changes co-primary endpoint for Phase 3 SENTRY trial to Abs-TSS; increases sample size to 350","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Co-primary endpoint changed from TSS50 to Abs-TSS following FDA alignment; SVR35 remains co-primary.","Phase 1 Selinexor+ruxolitinib data showed 79% SVR35 (n=14) and 18.5-point average Abs-TSS improvement (n=9) at week 24.","Total sample size increased to ~350 patients to improve statistical power; top-line data still expected in 2H 2025.","Safety profile remains consistent with no new signals; change supported by key investigators and MPN Research Foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206969,"accession_number":"0001193125-24-220534","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Karyopharm receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1.00 for 32 consecutive business days, violating Bid Price Rule 5450(a)(1).","Company has 180 days, until March 17, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","Failure to cure may allow a 180-day extension if stock moves to Nasdaq Capital Market and meets other listing standards.","Company may consider a reverse stock split, but there is no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206968,"accession_number":"0001193125-24-209907","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Karyopharm CFO Michael Mason to resign Nov 5; transition agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Mason, EVP/CFO/Treasurer, notified resignation effective November 5, 2024; will serve until then.","Company initiated search for a successor CFO.","Transition agreement provides $100,000 lump sum payable on Nov 6, 2024, if employed through resignation.","Mason to enter consulting agreement through March 1, 2025, with continued vesting of equity awards.","Consulting fee: hourly pay after 5th hour each month; equity vesting continues during consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206967,"accession_number":"0001193125-24-194427","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).","Net income $23.8M ($0.15 basic EPS) vs net loss $32.6M in Q2 2023; includes $44.7M non-cash gain on debt extinguishment.","Raises FY2024 total revenue guidance low end to $145M from $140M; lowers R&D/SG&A expense guidance to $250-265M from $260-280M.","Phase 3 SENTRY (myelofibrosis) top-line data on track for 2H 2025; XPORT-EC-042 (endometrial) top-line delayed to early 2026 due to screen failures.","Debt refinancing extended majority of maturities to 2028/2029; cash $152.5M; cash runway into Q1 2026 (excl. $49.5M debt payments)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":75912000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224263,"accession_number":"0001193125-24-151049","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Karyopharm shareholders approve 6M share increase in equity plan, 5M in ESPP, and option exchange","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Class II directors: Deepika R. Pakianathan, Richard Paulson, Chen Schor (all three-year terms).","Amendment to 2022 Equity Plan approved: adds 6,000,000 shares for issuance.","ESPP Amendment approved: adds 5,000,000 shares for issuance.","Stockholders approved a one-time stock option exchange program for non-executive officer employees.","Ratified Ernst & Young as independent auditor for FY2024 (87.7M for, 2.5M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224262,"accession_number":"0001193125-24-138211","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Karyopharm closes $148M debt exchange for new 6% notes due 2029 and warrants, plus $100M credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged ~$148M of 3.00% convertible notes due 2025 for $111M of new 6.00% secured convertible notes due 2029.","Issued warrants to purchase up to ~46M shares of common stock as part of the exchange.","Entered into a $100M senior secured credit facility, with proceeds used partly to repay HCR facility and for general purposes.","The exchange extends debt maturity from 2025 to 2029, improving near-term liquidity but increasing interest cost and adding dilution potential.","New notes are secured and carry a 6% coupon versus the 3% on the exchanged notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224261,"accession_number":"0001193125-24-133791","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Karyopharm closes $100M term loan, exchanges $148M old notes for $111M new 6% notes + warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M senior secured term loan at SOFR+9.25%, matures May 2028; liquidity covenant $25M minimum.","Exchanged ~$148M of 3% 2025 notes for ~$111M of 6% 2029 secured notes and warrants for ~46M shares at $1.10 strike.","New notes convertible at $2.25/share (105% premium to $1.10 closing price on May 7); redemption make-whole payable.","Used $49.5M cash + $15M term loan + $5M new notes to cut HCRx obligations; remaining HCRx balance ~$128.3M.","Issued 6.87M shares to financial advisor J. Wood Capital as advisory fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224260,"accession_number":"0001193125-24-133784","cik":1503802,"company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).","Net loss $37.4M ($0.32 per share) vs $34.1M ($0.30 per share) in Q1 2023; R&D expenses $35.4M, SG&A $29.5M.","Reaffirms FY2024 guidance: total revenue $140-160M; XPOVIO net product revenue $100-120M; R&D+SG&A $260-280M.","Completed refinancing: extended majority of debt maturities to 2028/2029 and amended HCRx royalty, reducing royalty rate from 12.5% to 7.0%.","Cash, equivalents, restricted cash and investments $149.3M as of March 31, 2024; cash runway expected into end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":33126000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202606699.32962137,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}